Dataset Information

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

ABSTRACT: We investigated the associations between methamphetamine (meth) use, immune function, and the dynamics of HIV and cytomegalovirus [CMV] in the blood and genital tract of HIV-infected ART-suppressed subjects. Self-reported meth use was associated with increased CD4(+) and CD8(+) T-cell proliferation (Ki67(+), p?

SUBMITTER: Massanella M

PROVIDER: S-EPMC4547398 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella Marta M Gianella Sara S Schrier Rachel R Dan Jennifer M JM Pérez-Santiago Josué J Oliveira Michelli F MF Richman Douglas D DD Little Susan J SJ Benson Constance A CA Daar Eric S ES Dube Michael P MP Haubrich Richard H RH Smith Davey M DM Morris Sheldon R SR

Scientific reports 20150824

We investigated the associations between methamphetamine (meth) use, immune function, and the dynamics of HIV and cytomegalovirus [CMV] in the blood and genital tract of HIV-infected ART-suppressed subjects. Self-reported meth use was associated with increased CD4(+) and CD8(+) T-cell proliferation (Ki67(+), p < 0.005), CD4(+) T-cell activation (CD45RA(-)CD38(+), p = 0.005) and exhaustion (PD-1(+), p = 0.0004) in blood, compared to non-meth users. Meth use was also associated with a trend toward ...[more]

PMID: 26299251

Dataset Information

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Publications

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
| S-EPMC4779972 | biostudies-other

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.
| S-EPMC7101154 | biostudies-literature

Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy.
| S-EPMC6391194 | biostudies-literature

Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
| S-EPMC5509215 | biostudies-literature

Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
| S-EPMC5375698 | biostudies-literature

Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children.
| S-EPMC6173292 | biostudies-literature

Efavirenz-metabolizing polymorphisms, viral suppression, and depression in HIV-infected individuals initiating antiretroviral therapy in southwestern Uganda
| S-EPMC5631238 | biostudies-literature

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
| S-EPMC4231123 | biostudies-literature

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-?B Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
| S-EPMC5899181 | biostudies-literature

Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.
| S-EPMC5035742 | biostudies-literature